Eli Lilly: collaboration with Dicerna Pharmaceuticals
(CercleFinance.com) - Eli Lilly and Dicerna Pharmaceuticals have announced a licensing and research collaboration for the discovery, development and marketing of potential new drugs for cardio-metabolic diseases, neuro-degeneration and pain.
Both the pharmaceutical groups will use Dicerna's proprietary GalXC technology platform to promote new drug targets towards their clinical development and marketing.
Dicerna will receive an upfront payment of 100 million dollars and a capital investment of the same amount. It will also be eligible for approximately $350 million per target in development and commercialization milestones, in addition to royalties.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Both the pharmaceutical groups will use Dicerna's proprietary GalXC technology platform to promote new drug targets towards their clinical development and marketing.
Dicerna will receive an upfront payment of 100 million dollars and a capital investment of the same amount. It will also be eligible for approximately $350 million per target in development and commercialization milestones, in addition to royalties.
Copyright (c) 2018 CercleFinance.com. All rights reserved.